https://www.selleckchem.com/pr....oducts/n6-methyladen
A key area of divergence was suitability for NA for women with type 2 and type 3VWD, with many respondents advising against the use of NA even with VWF supplementation (29% type 2VWD, 37% type 3VWD) but others advising use once plasma VWF activity was 50IU/dL (57% type 2VWD; 50% type 3VWD). This survey highlighted areas of uncertainty surrounding common management issues for pregnant women with VWD. These data underscore the need for international collaborative research efforts focused on peripartum management to improve
Like
Comment
Share
